These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P; Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852 [TBL] [Abstract][Full Text] [Related]
6. Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012. Robert P; Hotchko M Transfusion; 2015 Jul; 55 Suppl 2():S6-12. PubMed ID: 26174899 [No Abstract] [Full Text] [Related]
7. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial. Poehlau D; Federlein J; Postert T; Sailer M; Bethke F; Kappos L; Haas J; Przuntek H Mult Scler; 1997 Apr; 3(2):149-52. PubMed ID: 9291171 [TBL] [Abstract][Full Text] [Related]
8. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Sørensen PS; Wanscher B; Schreiber K; Blinkenberg M; Jensen CV; Ravnborg M Mult Scler; 1997 Apr; 3(2):145-8. PubMed ID: 9291170 [TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504 [TBL] [Abstract][Full Text] [Related]
11. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Francis GS; Freedman MS; Antel JP Mult Scler; 1997 Dec; 3(6):370-6. PubMed ID: 9493636 [TBL] [Abstract][Full Text] [Related]
12. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. Sorensen R J Manag Care Pharm; 2007 Apr; 13(3):278-83. PubMed ID: 17407395 [No Abstract] [Full Text] [Related]